Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

Introduction Brodalumab is a monoclonal antibody that targets the subunit A of interleukin-17A receptor (IL17RA), inhibiting signaling various isoforms IL-17 family. It has been approved for treatment moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab real-life setting are still limited. Methods The aim this study was to evaluate effectiveness and safety psoriasis. We also assessed drug survival 3 years timespan. conducted retrospective multicenter 606 patients followed up at 14 Italian dermatology units, all treated with according guidelines. Patients’ demographics disease characteristics were retrieved from electronic databases. At baseline weeks 12, 24, 52, 104 156, we area severity index (PASI) score investigated adverse events. proportions reaching 75, 90 100% (PASI PASI 100, respectively) improvement PASI, compared baseline, recorded. Results week 63.53% reached 49.17% 100. After treatment, 65.22% maintained complete skin clearance, 91.30% had an absolute 2 or less. Patients naïve biological therapies better clinical responses 24 52. no significant differences observed. Body mass did not interfere throughout study. No new findings 36 months, 85.64% our brodalumab. Conclusion Our confirm largest cohort date, 156 weeks.